Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | AMY2A | P04746 | 3/20 | 0.43 |
| ▸ | FGF1 | P05230 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089439 | 1.00 | CA2 (0.53) | CA2LGALS8LGALS3LGALS4MAPT | |
| SCHEMBL29068320 | 1.00 | CA2 (0.53) | CA2LGALS8LGALS3LGALS4MAPT | |
| SCHEMBL4761249 | 1.00 | CA2 (0.53) | CA2LGALS8LGALS3LGALS4MAPT | |
| Cellobiose SCHEMBL15211052 | 0.99 | CA2 (0.52) | CA2LGALS8LGALS3LGALS4MAPT | |
| SCHEMBL30089360 | 0.95 | CA2 (0.50) | CA2LGALS8LGALS3LGALS4MAPT | |
| SCHEMBL30089438 | 0.95 | CA2 (0.49) | CA2LGALS8LGALS3LGALS4MAPT | |
| SCHEMBL26264978 | 0.91 | CA2 (0.47) | CA2LGALS8LGALS3LGALS4MAPT | |
| Cellobiose SCHEMBL4761241 | 0.88 | LGALS8 (0.54) | CA2LGALS8LGALS3LGALS4MAPT | |
| Maltose SCHEMBL9704098 | 0.86 | LGALS8 (0.53) | CA2LGALS8LGALS3LGALS4MAPT | |
| SCHEMBL25241935 | 0.85 | CA2 (0.47) | CA2LGALS3FGF1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646037-B1 | use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis. | UNIV AUSTRALIAN NATIONAL (AU) | 2019-01-09 | — | — | EP | claimed |
| US-9226939-B2 | Histone inhibition | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2016-01-05 | — | — | US | claimed |
| US-20130338097-A1 | HISTONE INHIBITION | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2013-12-19 | — | — | US | claimed |
| EP-2646037-A1 | HISTONE INHIBITION | The Australian National University (AU) | 2013-10-09 | — | — | EP | claimed |
| WO-2012071611-A1 | HISTONE INHIBITION | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2012-06-07 | — | — | WO | claimed |
| CN-111479574-B | Compounds for the treatment and prevention of extracellular histone mediated pathologies | 澳大利亚国立大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-117462563-A | Compounds for the treatment and prevention of extracellular histone mediated pathologies | 澳大利亚国立大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-117427084-A | Compounds for the treatment and prevention of extracellular histone mediated pathologies | 澳大利亚国立大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-116813675-B | Compound crystal form and preparation, composition and application thereof | 北京远大九和药业有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117088925-A | Compound crystal form and preparation, composition and application thereof | 北京远大九和药业有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116813675-A | Compound crystal form and preparation, composition and application thereof | 北京远大九和药业有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230255992-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2023-08-17 | — | — | US | disclosed |
| EP-3723768-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | The Australian National University (AU) | 2020-10-21 | — | — | EP | disclosed |
| CN-111479574-A | Compounds for the treatment and prevention of extracellular histone mediated pathologies | 澳大利亚国立大学 | 2020-07-31 | — | — | CN | disclosed |
| WO-2019113645-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2019-06-20 | — | — | WO | disclosed |
| EP-2646037-B1 | use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis. | UNIV AUSTRALIAN NATIONAL (AU) | 2019-01-09 | — | — | EP | disclosed |
| US-9226939-B2 | Histone inhibition | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2016-01-05 | — | — | US | disclosed |
| US-20130338097-A1 | HISTONE INHIBITION | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2013-12-19 | — | — | US | disclosed |
| EP-2646037-A1 | HISTONE INHIBITION | The Australian National University (AU) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012071611-A1 | HISTONE INHIBITION | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338097-A1 | HISTONE INHIBITION | H1-5, H1-3, H1-2 | CA2 2445/4885LGALS8 3263/4885LGALS3 3126/4885 |
| US-20230255992-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | HMGB1, HDAC2, H1-3 | CA2 1565/4885LGALS8 1839/4885LGALS3 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.